combined gemcitabine, a first-line agent for pancreatic cancer, with AdipoRon to enhance growth inhibition in human PDAC cell lines, which may be associated with the AdipoRon mediated p44/42 MAPK(ERK1/2) pathway (72). Here, MAPK3 is linked to pancreatic neoplasm.